title: Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas.
abstract: Low-grade serous ovarian cancer is a recently described histological subtype of ovarian cancer that is clinically and molecularly distinct from the 4 other main histological subtypes (high-grade serous, clear cell, endometrioid, and mucinous). In particular, it differs from high-grade serous ovarian cancer in that it presents at a much younger age, is more indolent, and is relatively chemoresistant. Very few clinical trials have been performed exclusively in this tumor type; and as such, specific data guiding optimal management are limited.
authors.affiliation: *University of Edinburgh Cancer Research UK Centre, MRC IGMM, Edinburgh, United Kingdom; †Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St Joseph's Hospital and Medical Center, Phoenix, AZ; ‡Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), Institut du Cancer de Montréal, Montreal, Quebec, Canada, Division of Gynecologic Oncology, Université de Montréal, Montreal, Quebec, Canada; §Dipartimento di Oncologia Uroginecologica, Istituto Nazionale per lo Studio e la Cura dei Tumori, Fondazione G Pascale, IRCCS, Napoli, Italy; ∥Division of Cancer Medicine, Peter MacCallum Cancer Centre, St. Andrews Place, East Melbourne, Australia; ¶Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany; #Department of Obstetrics and Gynecology, Tampere University Hospital, Tampere, Finland; **Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, South Korea; ††Université Paris Descartes, Assistance Publique-Hôpitaux de Paris, Paris, France; ‡‡The Beatson West of Scotland Cancer Centre, Gartnavel Hospital, University of Glasgow, Glasgow, United Kingdom; §§Département d'Oncologie médicale adulte, Centre Léon Bérard, Lyon, France; and ∥∥Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Charlie
authors.initials: C
authors.lastname: Gourley
authors.forename: John
authors.initials: J
authors.lastname: Farley
authors.forename: Diane M
authors.initials: DM
authors.lastname: Provencher
authors.forename: Sandro
authors.initials: S
authors.lastname: Pignata
authors.forename: Linda
authors.initials: L
authors.lastname: Mileshkin
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.forename: Johanna
authors.initials: J
authors.lastname: Maenpaa
authors.forename: Jae-Weon
authors.initials: JW
authors.lastname: Kim
authors.forename: Eric
authors.initials: E
authors.lastname: Pujaide-Lauraine
authors.forename: Rosalind M
authors.initials: RM
authors.lastname: Glasspool
authors.forename: Isabelle
authors.initials: I
authors.lastname: Ray-Coquard
authors.forename: David
authors.initials: D
authors.lastname: Gershenson
mesh_terms: D003131:Combined Modality Therapy; D018284:Cystadenocarcinoma, Serous / Q000473:pathology* / Q000628:therapy; D005260:Female; D006801:Humans; D008495:Medical Oncology; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000473:pathology* / Q000628:therapy; D010534:Peritoneal Neoplasms / Q000473:pathology* / Q000628:therapy; D017410:Practice Guidelines as Topic; D012955:Societies, Medical